IUdR/BUdR Cell Cycle Labelling - Full Text View

Purpose

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Condition	Intervention
Hematologic Malignancies	Drug: Chemotherapy for hematologic malignancy

MedlinePlus related topics:

Cancer

ChemIDplus related topics:

Bromodeoxyuridine Idoxuridine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Single Group Assignment, Pharmacodynamics Study

Official Title:	Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling

Further study details as provided by M.D. Anderson Cancer Center:

Estimated Enrollment:	180
Study Start Date:	October 1991

Detailed Description:

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Histologic proof of one of:

AML, ALL, or AUL
MDS or CMML
CML
OR undergoing bone marrow transplantation.

Participants should be:

off therapy for at least two weeks
At least 18 years old or older
Using adequate contraception if of child-bearing capability.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00042250

Locations


United States, Texas
	M.D. Anderson Cancer Center
	Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

Investigators


Study Chair:	Michael Andreeff, MD, PhD	U. T. M. D. Anderson Cancer Center

More Information

M. D. Anderson Cancer Center This link exits the ClinicalTrials.gov site

Study ID Numbers:	DM91-102
First Received:	July 24, 2002
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00042250
Health Authority:	United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:

Cell Cycle Interphase

G0

G1

G2

S Phase

Study placed in the following topic categories:

Bromodeoxyuridine

Hematologic Neoplasms

Hematologic Diseases

Idoxuridine

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on September 05, 2008

Sponsored by:	M.D. Anderson Cancer Center
Information provided by:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00042250